Navigation Links
YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
Date:12/6/2010

ORLANDO, FL, Dec. 6 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM) today announced positive interim data from the first 60 patients enrolled in the Phase I/II trial for its JAK1/JAK2 inhibitor, CYT387, in myelofibrosis. The results were reported today in an oral presentation at the 52nd American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida.

"Anemia is the most serious symptom associated with myelofibrosis, so I am highly encouraged by the emerging activity profile of CYT387, which uniquely continues to demonstrate a substantial ability to improve anemia while producing similar results to its peers in reducing spleen size and controlling constitutional symptoms," noted Dr. Alayew Tefferi, Chair of the Study. "I also encourage YM to evaluate CYT387 in other diseases where anemia has a significant impact."

"These unprecedented results highlight the potential safety and efficacy advantages of CYT387 compared with other JAK inhibitors. If CYT387 continues to demonstrate this unique anemia benefit in larger trials, it may ultimately serve as a drug of choice for the majority of patients with myelofibrosis who find anemia problematic," said Dr. Nick Glover, President and CEO of YM BioSciences. "We look forward to updated data from the full 140 patient trial in calendar mid-2011."

Patient Characteristics:

The presentation described interim results for the first 60 patients enrolled in the dose escalation (n=21) and dose confirmation (n=39) portions of the 140 patient Phase I/II trial, for which recruitment is ongoing. In the dose-confirmation phase, subjects were started at one of two dose levels that were deemed clinically effective: 150 mg/day (n=18) and 300 mg/day (n=21). Thirty-three subjects (55%) were red cell transfusion-dependent at study entry. Forty-five subjects (75%) expressed the JAK2V617F mutation.
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
2. Ardea Biosciences to Present at Two Upcoming Investor Conferences
3. YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
4. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
5. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
6. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
7. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
8. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
9. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
10. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
11. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... PHILADELPHIA, Oct. 29 GlaxoSmithKline (NYSE:,GSK) (LSE: GSK) ... announced,today that they have entered into a definitive ... approximately $57 million (pounds Sterling 35,million) through a ... This strategic,acquisition will strengthen GSK,s effort to develop ...
... BioAuthorize,Holdings, Inc. and its wholly owned ... high-tech voice biometric security company,providing online payment ... board of directors and restructured its executive ... implementation of its newly developed,biometric authentication services., ...
... Calif., Oct. 29 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ... For the third quarter ended September 30, 2008, ... $0.15 per share, compared to a,net loss of $4.3 ... in 2007.,As of September 30, 2008, the company had ...
Cached Biology Technology:GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C 2GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C 3GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C 4BioAuthorize Holdings, Inc. Names New Directors and Executive and Unveils Modification to Its Voice Biometric Authentication Service 2BioAuthorize Holdings, Inc. Names New Directors and Executive and Unveils Modification to Its Voice Biometric Authentication Service 3BioAuthorize Holdings, Inc. Names New Directors and Executive and Unveils Modification to Its Voice Biometric Authentication Service 4BioAuthorize Holdings, Inc. Names New Directors and Executive and Unveils Modification to Its Voice Biometric Authentication Service 5Sangamo BioSciences Reports Third Quarter 2008 Financial Results 2Sangamo BioSciences Reports Third Quarter 2008 Financial Results 3Sangamo BioSciences Reports Third Quarter 2008 Financial Results 4Sangamo BioSciences Reports Third Quarter 2008 Financial Results 5Sangamo BioSciences Reports Third Quarter 2008 Financial Results 6Sangamo BioSciences Reports Third Quarter 2008 Financial Results 7
(Date:4/15/2014)... April 15, 2014, Irvine, Calif. UC Irvine neurobiologists ... positive results when transplanted into the brains of mice ... pre-clinical trial is published in the journal Stem ... been shown to work in two different mouse models. ... forms of dementia, is associated with accumulation of the ...
(Date:4/15/2014)... Hartford, Connecticut, a Puerto Rican community is creating a ... so authentic it has caught the attention of scientists. ... Anderson (University of Connecticut) took a close look at ... Hartford and uncovered evidence that gives new meaning to ... years: home is in the kitchen. , "Culinary preferences ...
(Date:4/15/2014)... as early as 2020 how high sea levels will ... of researchers including Florida International University scientist Rene Price. ... Foundation,s (NSF) Florida Coastal Everglades Long-Term Ecological Research (LTER) ... ecosystems from coral reefs to deserts, mountains to salt ... level rise is one of the most certain consequences ...
Breaking Biology News(10 mins):UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2The human food connection: A new study reveals more about our relationship to food 2The human food connection: A new study reveals more about our relationship to food 3Long-term predictions for Miami sea level rise could be available relatively soon 2
... University of Maryland Center for Environmental Science researchers gives ... Bay ecological conditions were slightly better than the previous ... healthy Bay. The Chesapeake Bay Health Report ... is nothing here from which we can take great ...
... Tyler J. and Frances F. Young Professor of Bacteriology ... the Virginia-Maryland Regional College of Veterinary Medicine at Virginia ... States Department of Agriculture to study the role biofilm ... (BRDC). The $374,000 grant will allow Inzana and ...
... bird feeders in their backyards each year, often out of ... survey of research on the topic finds that feeding may ... Published as a Frontiers in Ecology and the ... Gillian Robb (Queens University Belfast, UK) and by Stuart Bearhop ...
Cached Biology News:Chesapeake Bay ecosystem health remains poor, but slightly improved in 2007 2Veterinary college researchers explore function of biofilm in bovine respiratory disease 2Food for thought 2
... The Captivate magnetic separator ... be used in conjunction with ... C-21474, C-21476) or other magnetic ... most 96-well microplates. Cell Biology ...
RABBIT ANTI RAT AQUAPORIN 5...
MOUSE ANTI S. NEWPORT SALMONELLA HADAR...
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20*...
Biology Products: